Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

NCT04498117 is registered in ClinicalTrials.gov with CanariaBio Inc. as lead sponsor.

NCT NCT04498117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Lead sponsor
CanariaBio Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 25, 2020
Completion date
August 26, 2028
Enrollment
615 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, ovarian epithelial, fallopian tube adenocarcinoma, fallopian tube neoplasms, fallopian tube serous adenocarcinoma, ovarian cancer, ovarian neoplasms, ovarian serous adenocarcinoma, peritoneal cancer, peritoneal carcinoma, peritoneal neoplasms